ARS Pharmaceuticals, Inc. (SPRY) Misses Q1 EPS by 1c

ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) reported Q1 EPS of ($0.35), $0.01 worse than the analyst estimate of ($0.34). Revenue for the quarter came in at $7.97 million versus the consensus estimate of $7.48 million.

For earnings history and earnings-related data on ARS Pharmaceuticals, Inc. (SPRY) click here.

You May Also Be Interested In

• Attention Long-Term Shareholders of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY): Bloom Energy Corporation (NYSE: BE); GPGI, Inc., f/k/a CompoSecure, Inc. (NYSE: GPGI; CMPO); and Insulet Corporation (NASD
• Holcim to acquire Fermacell from James Hardie for EUR 840M
• Blue Moon Metals cleared to build at Nevada tungsten project